Tipelukast - MediciNova

Drug Profile

Tipelukast - MediciNova

Alternative Names: KCA-757; MN-001

Latest Information Update: 21 Jun 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Kyorin Pharmaceutical
  • Developer MediciNova
  • Class Anti-inflammatories; Antiasthmatics; Antifibrotics; Small molecules
  • Mechanism of Action 5-lipoxygenase inhibitors; Leukotriene D4 receptor antagonists; Leukotriene receptor antagonists; Phospholipase C inhibitors; Thromboxane A2 receptor antagonists; Type 3 cyclic nucleotide phosphodiesterase inhibitors; Type 4 cyclic nucleotide phosphodiesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis

Highest Development Phases

  • Phase II Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis
  • No development reported Interstitial cystitis
  • Discontinued Asthma

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 19 Jun 2018 MediciNova receives patent allowance for tipelukast in Japan
  • 11 Apr 2018 Efficacy data from a phase II trial in Non-alcoholic steatohepatitis presented at the The International Liver Congress (ILC-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top